# NIH Reporter #3P30CA134274-18S4

Tumor Immunology and Immunotherapy Program

**Recipient:** University of Maryland Baltimore

**Award Amount:** $179,423.00
**Ceiling:** $179,423.00

**Awarded:** August 20, 2026

**Identifier:** 3P30CA134274-18S4

Award to University of Maryland Baltimore for the Tumor Immunology and Immunotherapy Program, focusing on developing immune-based cancer treatments through innovative research and clinical trials.

### Description

The Tumor Immunology and Immunotherapy (TII) Program is an interdisciplinary initiative focused on innovative basic science research and translational/clinical trials. The program aims to develop immune-based strategies for monitoring and treating cancer, with research focuses on cell-based and regulatory pathway-targeted immunotherapies, immune regulation calibration, and the roles of infection and inflammation in cancer development. The program includes 35 members conducting cancer-focused research supported by approximately $16.6 million annually.

[View original record](https://reporter.nih.gov/search/0C83gI3MXki4-tEhFD4UKQ/project-details/11595396)